동종 세포 치료 기술 시장 : 전략적 인사이트와 예측(2026-2031년)

The Allogeneic Cell Therapy Technologies market is forecast to grow at a CAGR of 12.8%, reaching USD 4.2 billion in 2031 from USD 2.3 billion in 2026.

The global allogeneic cell therapy technologies market is emerging as a transformative segment within regenerative medicine, offering scalable and off-the-shelf therapeutic solutions derived from donor cells. Unlike autologous therapies, allogeneic approaches enable mass production, standardized manufacturing, and immediate availability, making advanced treatments more accessible and cost-efficient. The market is gaining strong traction due to increasing demand for innovative therapies for cancer, autoimmune disorders, and rare genetic diseases. Expanding clinical pipelines, rising investments from biotechnology and pharmaceutical companies, and supportive regulatory developments are further strengthening the growth trajectory. Advances in gene editing and cell engineering technologies are also enhancing the safety, efficacy, and durability of these therapies, positioning allogeneic platforms as a key pillar of next-generation therapeutics.

Market Drivers

A primary driver is the growing demand for scalable and cost-effective therapies. Allogeneic cell therapies enable production from a single donor for multiple patients, significantly reducing manufacturing complexity and treatment timelines while improving accessibility.

The increasing global burden of chronic and life-threatening diseases is another key growth factor. Rising incidence of cancer, autoimmune conditions, and rare genetic disorders is creating strong demand for innovative treatment options, where allogeneic therapies offer promising clinical outcomes.

Technological advancements in gene editing and cell engineering are further accelerating market expansion. Innovations such as CRISPR, TALENs, and other genome editing tools are enabling the development of immune-evasive and universal donor cells, improving therapeutic performance and reducing the risk of rejection.

Additionally, increasing funding from venture capital firms, government bodies, and pharmaceutical companies is supporting research, clinical trials, and commercialization efforts across the value chain.

Market Restraints

Despite strong growth potential, the market faces several challenges. The risk of immune rejection and graft-versus-host disease remains a critical concern, as incompatibility between donor and recipient cells can lead to serious complications.

High development and manufacturing costs also act as a barrier. Advanced infrastructure, complex bioprocessing systems, and extensive clinical trials require substantial capital investment, limiting participation from smaller companies.

Regulatory complexity further constrains market expansion. Stringent approval requirements for cell-based therapies increase development timelines and compliance costs, delaying commercialization.

Technology and Segment Insights

The market is segmented by cell type, technology, application, and geography. By application, oncology represents the fastest-growing segment, driven by the increasing use of allogeneic therapies such as CAR-T and CAR-NK cells for cancer treatment. These therapies offer rapid availability compared to autologous approaches, improving treatment timelines for critical conditions.

Technological advancements in gene editing, cell expansion, cryopreservation, and immune evasion techniques are enhancing the performance and scalability of allogeneic therapies. The integration of automation and closed-system manufacturing is also improving production efficiency and consistency.

From a regional perspective, North America holds a leading position due to strong biotechnology infrastructure, high R&D investment, and supportive regulatory frameworks. Asia-Pacific is emerging as a high-growth region, supported by increasing healthcare investments, expanding clinical trial activity, and favorable cost structures.

Competitive and Strategic Outlook

The competitive landscape is characterized by a strong presence of biotechnology firms and pharmaceutical companies focusing on innovation and strategic collaboration. Key players include Allogene Therapeutics, Adicet Bio, CRISPR Therapeutics, Astellas Pharma, Gamida Cell, and Fate Therapeutics.

Strategic initiatives include partnerships, acquisitions, and investments aimed at accelerating product development and expanding clinical pipelines. Companies are also focusing on integrating advanced gene editing technologies and scalable manufacturing platforms to enhance product efficiency and reduce costs.

Emerging trends include the development of universal donor cell lines, expansion into new therapeutic areas beyond oncology, and increased adoption of automated biomanufacturing systems.

Conclusion

The global allogeneic cell therapy technologies market is set for steady growth, driven by increasing demand for scalable therapies, advancements in gene editing technologies, and expanding clinical applications. While immune-related risks, high costs, and regulatory challenges remain key barriers, continued innovation and strong investment activity will support long-term market expansion.

Key Benefits of this Report

• Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2025 and forecast data from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ALLOGENEIC CELL THERAPY TECHNOLOGIES MARKET BY CELL TYPE

• 5.1. Introduction
• 5.2. T Cells
• 5.3. Natural Killer (NK) Cells
• 5.4. Hematopoietic Stem Cells (HSCs)
• 5.5. Mesenchymal Stem Cells (MSCs)
• 5.6. Induced Pluripotent Stem Cells (iPSCs)

6. ALLOGENEIC CELL THERAPY TECHNOLOGIES MARKET BY TECHNOLOGY

• 6.1. Introduction
• 6.2. Gene Editing Technologies
• 6.3. Cell Engineering & Expansion Technologies
• 6.4. Cell Preservation & Cryopreservation
• 6.5. Viral Vector Engineering
• 6.6. Non-Viral Gene Delivery Systems

7. ALLOGENEIC CELL THERAPY TECHNOLOGIES MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Oncology
• 7.3. Autoimmune Diseases
• 7.4. Cardiovascular Diseases
• 7.5. Neurological Disorders
• 7.6. Rare Genetic Disorders
• 7.7. Infectious Diseases

8. ALLOGENEIC CELL THERAPY TECHNOLOGIES MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Allogene Therapeutics Inc.
• 10.2. Adicet Bio, Inc.
• 10.3. CRISPR Therapeutics AG
• 10.4. Astellas Pharma Inc.
• 10.5. Gamida Cell Ltd.
• 10.6. Atara Biotherapeutics, Inc.
• 10.7. Fate Therapeutics
• 10.8. Cellectis
• 10.9. Celularity Inc.
• 10.10. Century Therapeutics

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations